3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
55
Endometrial Neoplasms
4
Polycystic Ovary Syndrome
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Recurrence
2
Neoplasms
2
Infertility
2
Carcinoma, Ductal, Breast
2
Breast Neoplasm Female
2
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Neoplasms by Site
1
Liposarcoma
1
Inflammatory Breast Neoplasms
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Cystadenocarcinoma, Serous
1
Colorectal Neoplasms
1
Carcinoma, Lobular
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Breast Diseases
1
Breast Cancer Female
1
Anovulation
1
Advanced Breast Carcinoma
1
Adenocarcinoma of Lung
1
Interventions
Radiotherapy
3
Radiation
3
palbociclib
2
Magnetic Resonance Spectroscopy
2
Immunoglobulin G
2
Doxorubicin
2
zimberelimab
1
talimogene laherparepvec
1
sotigalimab
1
ribociclib
1
pazopanib
1
eribulin
1
enzalutamide
1
durvalumab
1
cemiplimab
1
abemaciclib
1
Specimen Handling
1
Radiotherapy, Intensity-Modulated
1
Nivolumab
1
Midazolam
1
Letrozole
1
Ipilimumab
1
Ifosfamide
1
Fulvestrant
1
Everolimus
1
Disulfides
1
CTLA-4 Antigen
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Liposarcoma
×
Letrozole
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled